News

Company News & Events

ORYZON appoints Eisai executive Vanessa Almendro Navarro to Board of Directors

17 April 2020

MADRID, SPAIN and CAMBRIDGE MA.

• Dr. Vanessa Almendro Navarro, PhD, MBA, is Director of Strategy and Operations at EISAI's Genetic Guided Discovery in Dementia (G2D2) Center in Boston

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with high unmet medical need, is pleased to announce the appointment of Dr. Vanessa Almendro Navarro, of Eisai US, as an independent director. Dra. Almendro will be Lead Director and member of the Remuneration and Nomination Committee.

 

Click here to see the full Press Release

 

Posted In: 
News
Investors

Share this story